Affinity for Hsp90

Hsp90 from porcine spleen extract was isolated by affinity capture on a purine-affinity media. The Hsp90 loaded media was then challenged with PF-04929113 at a given concentration, ranging from 0.8 to 500 μM, and the amount of Hsp90 liberated at each concentration was determined by Bradford protein assay. The resulting IC50 values were corrected for the ATP ligand concentration and presented as apparent Kd values.

Cell lines

MCF-7, SW620, K562, SK-MEL-5 and A375 cancer cell lines

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reaction Conditions

0 ~ 300 nM; 72 or 144 hrs

Applications

In a broad range of cancer cell lines (MCF-7, SW620, K562, SK-MEL-5 and A375 cells), PF-04929113 showed potent antiproliferative activity, with the IC50 values being 16, 19, 23, 25 and 51 nM, respectively.

Animal models

Fox Chase SCID mice (6 ~ 7 weeks old) inoculated subcutaneously with 5 × 106 MM.1S cells

Dosage form

20 or 40 mg/kg; p.o.; 3 times per week, for 3 weeks

Applications

PF-04929113 inhibited human MM cell growth and angiogenesis in vivo.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

PF-04929113 is an inhibitor of Hsp90 [1].

PF-04929113 is a water-soluble and oral pre-PF-04928473, which can be rapidly absorbed and converted into PF-04928473 after oral administration. In BT-474 xenograft mice, PF-04928473 induced the degradation of HER2 client protein. No obvious toxicity was observed when the dose reached 150mg/kg. PF-04928473 at 100mg/kg resulted in complete tumor growth inhibition and local tumor regression in some mice. In H1650 xenograft mice, PF-04928473 also showed significant anti-tumor activity. In addition, as an inhibitor of Hsp90, PF-04928473 inhibits p-ERK and p-Akt in vivo, reduces CD31+ cells and MVD, and has an effect on angiogenesis [1,2].

References:
[1] Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 2008 Jan 1;14(1):240-8.
[2] Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 2009 Jan 22;113(4):846-55.